Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TetraVax-DV-TV003
- Development stage
- Unknown
- Lead developer
- National Institute of Allergy and Infectious Diseases
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
TetraVax-DV-TV003 is a live-attenuated tetravalent vaccine developed by the National Institute of Allergy and Infectious Diseases (NIAID) for the prevention of dengue fever. The vaccine is composed of four specific attenuated dengue virus strains: rDEN1Δ30, rDEN2/4Δ30(ME), rDEN3Δ30/31-7164, and rDEN4Δ30. It is designed to elicit a balanced immune response, including neutralizing antibodies, against all four dengue serotypes (DENV-1, DENV-2, DENV-3, and DENV-4) following a single subcutaneous dose. Due to the structural similarities between dengue and Zika viruses, which are both members of the Flaviviridae family, TV003 is being evaluated in Phase 1 clinical trials to determine if the immunity it provides can cross-protect against Zika virus infection.
- Brand names
- Butantan-DV
- Other names
- Live Attenuated Tetravalent Dengue Vaccine TV003NIAID Tetravalent Dengue Vaccine
02
Targets
Dengue virus serotype 4 envelope/premembrane antigensDengue virus serotype 3 envelope/premembrane antigensDengue virus serotype 2 envelope/premembrane antigensZIKV E (Zika virus envelope protein)Dengue virus nonstructural proteinsDengue virus serotype 1 envelope/premembrane antigens
Beyond the preview
Go deeper on TetraVax-DV-TV003.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TetraVax-DV-TV003.